The possibility of treating cancer by stimulating the patient's response to his own tumour cells has led to the use of BCG as an active non-specific immunotherapeutic agent. Preliminary results indicate that length of survival and remission duration may be prolonged when BCG is used in the treatment of acute myelogenous leukaemia (AML) (Powles et al, 1973; Gutterman et al, 1974a; Vogler and Chan, 1974) and malignant melanoma (Gutterman et al, 1974b) although more comprehensive studies are needed before definite conclusions can be reached. Hepatic dysfunction, including granulomatous hepatitis, has been seen in three patients receiving BCG by intratumour injection Sparks et al, 1973) . This paper describes a prospective study of liver function and an attempt to define the extent of granuloma formation in a group of patients with AML receiving BCG by the intravenous route.
Patients and methods
Eleven patients reached complete remission (MRC, 1963) from acute myeloblastic leukaemia after receiving five to nine courses of daunorubicin, 1-5 mg/kg by a single intravenous infusion, and cytosine Received for publication 30 December 1975 arabinoside, 1.0 mg/kg every 12 hours for five days intravenously. Intervals between treatment were from five to seven days. Maintenance chemotherapy was given on one day of each month with daunorubicin at the remission induction dosage and with cytosine arabinoside, 1-0 mg/kg as an eight-hour infusion in saline. When a total dose of 600 mg daunorubicin had been reached, doxorubicin, 10 mg/kg, was substituted. In addition, 14 days after each. chemotherapy, all patients received BCG (Glaxo freeze-dried preparation containing 4-9 x 106 live organisms/ml). This was given intravenously using the careful technique previously described (Whittaker et al, 1973 but during the month between BCG treatments all patients remained well. We were unable to culture BCG organisms from venous blood samples taken more than one hour after BCG treatment, and neither BCG nor tubercle bacilli could be isolated from the marrow or liver biopsy specimens. Recently Mycobacterium tuberculosis has been grown from the sputum of one patient (case 8).
Discussion
The complications of BCG in patients with malignant disease are essentially similar whether the route of administration is intradermal, intratumour or intravenous (Powles et al, 1973; Gutterman et al, 1974a ; Vogler and Chan, 1974; Gutterman et al, 1974b ; Whittaker and Slater, unpublished observation), although intratumour injection has caused more severe reactions than intradermal injection when high concentrations of BCG organisms have been given (Gutterman et al, 1974b The mechanism of granuloma formation is uncertain, but it seems likely that it represents a hypersensitivity reaction Muggleton et al, 1975) , possibly to dead organisms contained in the BCG vaccine, and the use of a preparation containing a relatively low concentration of dead organisms, such as that used in our study, has been recommended (Muggleton et al, 1975 (Wallgren, 1955; Bouton et al, 1963; Bonnevier et al, 1964; Carlgren et al, 1966) . Although Hunt et al (1973) did not consider their patients to be immunoincompetent, nevertheless all three were PPD negative. The most extensive and well-formed granulomas in our study occurred in patients who were also PPD negative initially, and until the relevance of these findings becomes more clear, great care should be taken when using BCG in this group. Antihistamine pretreatment should be routine when using BCG by intratumour or intravenous (Muggleton et al, 1975) injection. If used by the intravenous route the careful procedure reported by us (Whittaker et al, 1973 ) may reduce unwanted side effects.
The place of BCG in the treatment of malignant disease remains unestablished and, although an increased incidence of second remissions in patients with acute leukaemia has been reported (Freeman et al, 1973; Hamilton Fairley, 1975) , its potential dangers require that great care should be taken in its use.
